13G Filing: Sabby Capital and Arca Biopharma Inc. (ABIO)

Page 4 of 9 – SEC Filing

12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO
CUSIP No.
00211Y4071.
NAME OF REPORTING PERSONSHal Mintz2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) [_]

(b) [X]

3.
SEC USE ONLY4.
CITIZENSHIP OR PLACE OF ORGANIZATIONUSANUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.
SOLE VOTING POWER06.
SHARED VOTING POWER 557,6527.
SOLE DISPOSITIVE POWER08.
SHARED DISPOSITIVE POWER 557,6529.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 557,65210.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (SEE INSTRUCTIONS)

[_]11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)4.7512.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN?

CUSIP No.
00211Y407

Item 1.
(a).
Name of Issuer:ARCA Biopharma, Inc.

(b).
Address of issuer’s principal executive offices:8001 Arista Place, Suite 200, Broomfield, CO 80021

Item 2.
(a).
Name of person filing:Sabby Healthcare Master Fund, Ltd.
Sabby Volatility Warrant Master Fund, Ltd.
Sabby Management, LLC
Hal Mintz

Follow Oruka Therapeutics Inc. (NASDAQ:ORKA)